September NRDD Article: Speedy validation sought for new cardiotoxicity testing strategy

"On 23 July 2013, the US Food and Drug Administration (FDA), the Health and Environmental Sciences Institute (HESI) and the Cardiac Safety Research Consortium (CSRC) presented a new paradigm for cardiotoxicity testing, with a lofty goal of validating and standardizing the new assays in 2 years' time. A drastic change from current requirements, the proposal entails two non-clinical solutions: an in silico model that will probably integrate as many as six individual ion channel assays and electrophysiological tests on stem-cell-derived cardiomyocytes  (Nature Rev. Drug Discov12, 565–567; 2013)."

Read the full article here:

Recent Stories
Congratulations 2021 Incoming Board Members!

SPS Announces 2020 Publication Award Recipients

Webinar of Interest! Exploring safety issues in antimicrobial drug development